Vinflunine

Research use only, not for human use.

The behavior of vinflunine in routine clinical practice resembles that of the pivotal phase III randomized study. Vinflunine（VFL）-EPR combination is feasible with manageable toxicity.

The behavior of vinflunine in routine clinical practice resembles that of the pivotal phase III randomized study. Vinflunine（VFL）-EPR combination is feasible with manageable toxicity. The antitumour activity was promising and supports further evaluation. It underscores a critical function for VFL in cell-cell adhesions of epithelial bladder tumour cells, suggesting a novel molecular mechanism by which VFL may impact upon EMT and metastasis.

——

——

——

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

——

——

——

162652-95-1

816.93

C45H54F2N4O8

>98% (HPLC)

DMSO: 100 mg/mL (103.4 mM)

——

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(CC(C[C@@H](C(F)(F)C)C7)([H])CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O

(-20℃)

With Ice Pack

≥ 2 years